Advantage Alpha Capital Partners LP Invests $285,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Advantage Alpha Capital Partners LP bought a new position in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 99,566 shares of the company's stock, valued at approximately $285,000. Advantage Alpha Capital Partners LP owned about 0.10% of Poseida Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PSTX. Marshall Wace LLP purchased a new stake in Poseida Therapeutics in the 2nd quarter worth approximately $31,000. Bayesian Capital Management LP purchased a new stake in Poseida Therapeutics during the first quarter worth $33,000. Rothschild Investment LLC purchased a new stake in Poseida Therapeutics during the second quarter worth $35,000. Principal Financial Group Inc. acquired a new stake in Poseida Therapeutics during the second quarter valued at $35,000. Finally, Intech Investment Management LLC purchased a new position in Poseida Therapeutics in the third quarter valued at $46,000. 46.87% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a "neutral" rating and set a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. BTIG Research restated a "neutral" rating on shares of Poseida Therapeutics in a research report on Tuesday. Cantor Fitzgerald cut Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday. Finally, William Blair reiterated a "market perform" rating on shares of Poseida Therapeutics in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $9.50.

Poseida Therapeutics Price Performance

Shares of NASDAQ PSTX traded down $0.05 during mid-day trading on Wednesday, reaching $9.33. The company's stock had a trading volume of 3,346,633 shares, compared to its average volume of 699,993. The stock has a 50-day moving average of $3.02 and a two-hundred day moving average of $3.01. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a market capitalization of $909.35 million, a P/E ratio of -14.81 and a beta of 0.54. Poseida Therapeutics, Inc. has a 1-year low of $1.87 and a 1-year high of $9.42.

Insider Activity

In related news, Chairman Mark J. Gergen sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares in the company, valued at approximately $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 2.90% of the company's stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.